Johnson & Johnson Market Cap ($574.95 Billion)
Market Cap & Net Worth: Johnson & Johnson (JNJ)
Johnson & Johnson market cap. Johnson & Johnson (NYSE:JNJ) has a market capitalization of $574.95 Billion ($574.95 Billion) as of November 4, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #29 globally and #21 in its home market, demonstrating a -0.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Johnson & Johnson's stock price $266.17 by its total outstanding shares 2409295102 (2.41 Billion). Also see how efficiently does Johnson & Johnson generate cash for how efficiently the company converts equity into cash flow.
Johnson & Johnson Market Cap History (2015–2026)
Johnson & Johnson market cap history from 2015 to 2026. Data shows growth from $193.36 Billion to $641.28 Billion (12.02% CAGR). Check JNJ stock price and chart for real-time trading data and today's change.
Index Memberships
Johnson & Johnson is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Composite Average
DJA
|
$17.85 Trillion | 3.22% | #7 of 65 |
|
DJC: Dow Jones-UBS Commodity Index
DJC
|
$24.95 Trillion | 1.52% | #8 of 65 |
|
Dow Jones Industrial Average
DJI
|
$23.21 Trillion | 2.31% | #8 of 30 |
|
ARCA Pharmaceutical
DRG
|
$3.45 Trillion | 16.68% | #2 of 24 |
|
S&P 500 Index
GSPC
|
$61.76 Trillion | 0.80% | #18 of 503 |
|
S&P 100
OEX
|
$44.38 Trillion | 1.14% | #17 of 101 |
Weight: Johnson & Johnson's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Johnson & Johnson Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Johnson & Johnson's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Johnson & Johnson to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.29x
Johnson & Johnson's market cap is 5.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
18.60x
Johnson & Johnson's market cap is 18.60 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $223.00 Billion | $71.89 Billion | $16.54 Billion | 3.10x | 13.48x |
| 2017 | $277.47 Billion | $76.45 Billion | $1.30 Billion | 3.63x | 213.44x |
| 2018 | $263.23 Billion | $81.58 Billion | $15.30 Billion | 3.23x | 17.21x |
| 2019 | $305.93 Billion | $82.06 Billion | $15.12 Billion | 3.73x | 20.23x |
| 2020 | $339.04 Billion | $82.58 Billion | $14.71 Billion | 4.11x | 23.04x |
| 2021 | $377.82 Billion | $78.74 Billion | $20.88 Billion | 4.80x | 18.10x |
| 2022 | $400.39 Billion | $79.99 Billion | $17.94 Billion | 5.01x | 22.32x |
| 2023 | $366.04 Billion | $85.16 Billion | $35.15 Billion | 4.30x | 10.41x |
| 2024 | $348.43 Billion | $88.82 Billion | $14.07 Billion | 3.92x | 24.77x |
| 2025 | $498.60 Billion | $94.19 Billion | $26.80 Billion | 5.29x | 18.60x |
Competitor Companies of JNJ by Market Capitalization
Companies near Johnson & Johnson in the global market cap rankings as of November 4, 2026. Also see Johnson & Johnson total assets for a full breakdown of the balance sheet.
Key companies related to Johnson & Johnson by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- AbbVie Inc (NYSE:ABBV): Ranked #43 globally with a market cap of $356.49 Billion USD.
- Novartis AG (MX:NVSN): Ranked #50 globally with a market cap of $330.48 Billion USD ( MX$5.74 Trillion MXN).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1409.38 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #43 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $286.00 |
| #50 | Novartis AG | MX:NVSN | $330.48 Billion | MX$3009.50 |
Market Capitalization of Johnson & Johnson (2015–2026)
Market capitalization of Johnson & Johnson from 2015 to today. Between 2015 and today, Johnson & Johnson's market cap moved from $193.36 Billion to $ 641.28 Billion, with a yearly change of 12.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $641.28 Billion | +28.62% |
| 2025 | $498.60 Billion | +43.10% |
| 2024 | $348.43 Billion | -4.81% |
| 2023 | $366.04 Billion | -8.58% |
| 2022 | $400.39 Billion | +5.97% |
| 2021 | $377.82 Billion | +11.44% |
| 2020 | $339.04 Billion | +10.82% |
| 2019 | $305.93 Billion | +16.22% |
| 2018 | $263.23 Billion | -5.13% |
| 2017 | $277.47 Billion | +24.43% |
| 2016 | $223.00 Billion | +15.33% |
| 2015 | $193.36 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Johnson & Johnson was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $574.95 Billion USD |
| MoneyControl | $574.95 Billion USD |
| MarketWatch | $574.95 Billion USD |
| marketcap.company | $574.95 Billion USD |
| Reuters | $574.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bow… Read more